We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 731

Validity of Sequenom patent still to be decided

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 27 2015

Although Sequenom has settled its dispute over U.S. Patent 6,258,540 with some parties (as I noted here), its case against Ariosa Diagnostics, Inc

Supreme Court calls for some deference in claim construction standard of review

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 22 2015

On January 20, 2015, the Supreme Court issued its decision in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., finding that the Federal Rules of Civil

Can any DNA claims still be patented?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 21 2015

In a decision issued December 17, 2014, in In Re BRCA1- And BRCA2-Based Hereditary Cancer Test Patent Litigation (Myriad II), the Federal Circuit

U.S. Supreme Court modifies Federal Circuit’s standard of review for claim construction in Teva v. Sandoz

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 20 2015

On January 20, 2015, resolving a long debated issue, the U.S. Supreme Court set aside the Federal Circuit’s de novo review of every aspect of a lower

Five things you need to know about the USPTO interim guidelines on 101

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 15 2015

The USPTO issued interim guidelines on 101 (“Interim Guidance”) on December 15, 2014. We summarized the Interim Guidance in this post here, and now

Pre-trial consolidation may run afoul of the America Invents Act

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 12 2015

The America Invents Act introduced a new statute, 35 U.S.C. 299, which provides that “accused infringers may not be joined in one action as

USPTO issues final Patent Term Adjustment rules under Novartis

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 12 2015

The USPTO has published final Patent Term Adjustment (PTA) rules addressing the treatment of Requests for Continued Examination (RCEs) under the

Federal Circuit finds "classic" reissue error

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 8 2015

In Fleming v. Escort Inc., the Federal Circuit noted that the error on which Fleming's reissue patents were based was a "classic" type of error

Three patent issues to watch in 2015

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 7 2015

Well, 2014 was a busy year in patent law, and it wasn't all good news for patent holders. The Supreme Court made 35 USC 101 a significant hurdle to

An early test for the USPTO’s eligibility analysis

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 21 2014

Just last week, the USPTO released its revised subject matter eligibility guidance (2014 Interim Guidance on Patent Subject Matter Eligibility